PMID- 28910952
OWN - NLM
STAT- MEDLINE
DCOM- 20190426
LR  - 20190426
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 97
IP  - 34
DP  - 2017 Sep 12
TI  - [Establishment of cut-off value of serum pro-gastrin-releasing peptide for 
      diagnosis of small cell lung cancer and evaluation on the clinical diagnosis 
      efficiency].
PG  - 2657-2662
LID - 10.3760/cma.j.issn.0376-2491.2017.34.004 [doi]
AB  - Objective: To determine critical reference value (cut-off value) of serum 
      pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase(NSE) in the 
      diagnosis of small cell lung cancer(SCLC). To evaluate the clinical significance 
      of serum levels of ProGRP and NSE in diagnosis and differential diagnosis in 
      SCLC. Methods: Three hundred and fifty-two SCLC patients, 163 non small cell lung 
      cancer(NSCLC)patients , 193 benign pulmonary disease patients and 140 healthy 
      people visiting in National Cancer Hospital were analyzed retrospectively from 
      January 2014 to July 2017.The levels of serum ProGRP and NSE of people were 
      determined using electrochemiluminescent immunoassay respectively . Reference 
      value ranges of the makers were determined by using the method of ROC curves. 
      Results: In NSCLC group, benign lung disease group, healthy control group and 
      mixed group (NSCLC+ lung benign diseases+ healthy control group) as a reference, 
      the cut-off values were 58.3, 62.3, 57.8, 61.3 ng/L. In the diagnosis and 
      differential diagnosis of SCLC and NSCLC, benign lung diseases, healthy controls 
      and mixed group, AUC of ProGRP was 0.940 (0.919-0.961), 0.941 (0.921-0.960), 
      0.959 (0.944-0.975), 0.946 (0.928-0.963) respectively. The sensitivities of 
      ProGRP were 86.4%, 84.9%, 86.4% and 84.7% respectively. The specificities of 
      ProGRP were 95.7%, 96.9%, 99.3%, 98% respectively. In all groups the Youden's 
      index of ProGRP and NSE were 0.821 vs 0.612, 0.818 vs 0.674, 0.857 vs 0.810, 
      0.827 vs 0.674. In healthy controls, no statistically significant difference was 
      found between ProGRP and NSE (P>0.05) in the diagnosis of AUC. However, in the 
      remaining 3 groups, the ProGRP diagnosis of AUC was significantly greater than 
      that of NSE (P<0.01). Compared with single marker detection, the sensitivity of 
      combined detection of ProGRP and NSE in diagnosis of SCLC increased to 95.5%, 
      94%, 96.6% and 94% in each group. There was no significant difference between 
      ProGRP and ProGRP+ NSE in the diagnosis of AUC when compared with the NSCLC group 
      and the mixed group (P>0.05). However, when combined with a healthy control group 
      and a benign lung disease group, the ProGRP+ NSE combination was the highest for 
      AUC diagnosis, compared with ProGRP and NSE (P<0.01). In the SCLC ED group serum 
      ProGRP and NSE levels[776.33(3 103.4)ng/L, 52.14(60.59)mug/L]were higher than 
      those in the SCLC LD group[295.59(799.65)ng/L, 23.36(22.97)mug/L], respectively 
      (all P<0.001). The serum ProGRP levels of N0, N1, N2 and N3 in TNM staging were 
      113.0(343.65), 167.04(724.56), 427.42(1 388.62), 735.99(1 709.95)ng/L 
      respectively (all P<0.001). Serum ProGRP and NSE levels were not statistically 
      different between the sex groups and the age groups (all P>0.05). Conclusion: To 
      establish the cut-off value of serum ProGRP is helpful for the diagnosis and 
      differential diagnosis of SCLC.
FAU - Shen, D
AU  - Shen D
AD  - Department of Laboratory, National Cancer Center/Cancer Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
FAU - Han, B B
AU  - Han BB
FAU - Chen, F
AU  - Chen F
FAU - Wei, B J
AU  - Wei BJ
FAU - Cui, C J
AU  - Cui CJ
FAU - Wang, G J
AU  - Wang GJ
FAU - Cui, W
AU  - Cui W
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - 80043-53-4 (Gastrin-Releasing Peptide)
RN  - EC 4.2.1.11 (Phosphopyruvate Hydratase)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Carcinoma, Non-Small-Cell Lung
MH  - Gastrin-Releasing Peptide
MH  - Humans
MH  - *Lung Neoplasms
MH  - Peptide Fragments
MH  - Phosphopyruvate Hydratase
MH  - Recombinant Proteins
MH  - Retrospective Studies
MH  - *Small Cell Lung Carcinoma
OTO - NOTNLM
OT  - Diagnosis
OT  - Neuron specific enolase
OT  - Pro-gastrin-releasing peptide
OT  - Reference values
OT  - Small cell lung carcinoma
EDAT- 2017/09/16 06:00
MHDA- 2019/04/27 06:00
CRDT- 2017/09/15 06:00
PHST- 2017/09/15 06:00 [entrez]
PHST- 2017/09/16 06:00 [pubmed]
PHST- 2019/04/27 06:00 [medline]
AID - 10.3760/cma.j.issn.0376-2491.2017.34.004 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2017 Sep 12;97(34):2657-2662. doi: 
      10.3760/cma.j.issn.0376-2491.2017.34.004.